Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Paratek Pharmaceuticals, Inc.

http://paratekpharma.com/

Latest From Paratek Pharmaceuticals, Inc.

Grünenthal Bolsters US Portfolio With Buyout Of Valinor

Deal snapshot: The German pain-management specialist is acquiring Valinor to gain additional geographic rights to the gastrointestinal drug Movantik and add to its US product portfolio.

M & A Business Strategies

Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna

Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.

Deal Watch Business Strategies

Lilly To Bolster IBD Pipeline With $3.2bn Morphic Bid

With only one inflammatory bowel disease product, Lilly is betting big on Morphic and its Phase II oral integrin MORF-057, which would directly compete with Takeda blockbuster Entyvio.

M & A Business Strategies

Ensho Joins Race To Develop An Oral Integrin Inhibitor For IBD

Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.

Deals StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Novacea, Inc.
    • Transcept Pharmaceuticals, Inc.
    • TransOral Pharmaceuticals, Inc.
UsernamePublicRestriction

Register